Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Cushing's Syndrome (CS) Market Outlook

Thelansis’s “Cushing's Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cushing's Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cushing's Syndrome (CS) Overview

Cushing's Disease (CD), the leading cause of endogenous Cushing's Syndrome (CS), results from the persistent overproduction of ACTH by a pituitary corticotroph adenoma. CD predominantly affects females, with a female-to-male ratio of 4-5:1, except in prepubertal patients, where males are more commonly affected. The peak age of onset occurs between 25 and 40 years. CD symptoms include typical CS features like central obesity, facial rounding, hypercatabolism signs, skin hyperpigmentation, and, in some cases, corticotroph macro-adenoma, neurological complications. Cushing's syndrome can present with varying signs and symptoms. Prolonged exposure to elevated cortisol levels leads to evident manifestations such as weight gain, thin extremities, a rounded face, fat accumulation around the neck, a fatty hump between the shoulders, easy bruising, wide purple stretch marks, mainly on the abdomen, breasts, hips, and under the arms, and muscle weakness. The exact pathogenesis of pituitary tumors remains largely unknown. Most pituitary adenomas are sporadic, although a small percentage (<5%) occur within familial syndromes like multiple endocrine neoplasia type 1 (MEN 1), caused by MEN1 gene mutations (11q13), familial isolated pituitary adenomas (FIPA), where 15% of patients have AIP gene mutations (11q13-32), and the recently described multiple endocrine neoplasia type 4 (MEN 4), linked to CDKN1B gene mutations. Endogenous Cushing's syndrome is traditionally classified as ACTH-dependent or ACTH-independent. ACTH-dependent cases account for 80%-85% of all instances. Among these, approximately 75%-80% stem from pituitary adenomas (Cushing's Disease or CD), 15%-20% from nonpituitary tumors (ectopic ACTH syndrome or EAS), and less than 1% from corticotropin-releasing hormone (CRH)-producing tumors. Most pituitary tumors arise sporadically, originating from a single mutated cell. Surgical removal of the source of excess glucocorticoids, whether a pituitary adenoma, nonpituitary ACTH-secreting tumor, or adrenal tumor(s), is the primary treatment for all forms of Cushing's syndrome. Transsphenoidal surgery yields an initial remission rate of 60%-80% (less than 15% in macroadenomas) with a relapse rate of up to 20% within a decade.

• In the United States, the reported incidence of Cushing's Disease ranges from 6.2 to 7.6 cases per million person-years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: